CT
VRTX icon

Colonial Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Colonial Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Hold
21
– – ﹤0.01% 759
2026
Q1 		$9.48K Sell
21
-32
-60% -$14.9K ﹤0.01% 771
2025
Q4 		$24.2K Sell
53
-17
-24% -$7.33K ﹤0.01% 659
2025
Q3 		$27.3K Buy
70
+38
+119% +$15.9K ﹤0.01% 629
2025
Q2 		$14.2K Buy
32
+13
+68% +$5.99K ﹤0.01% 725
2025
Q1 		$9.21K Sell
19
-68
-78% -$31.7K ﹤0.01% 766
2024
Q4 		$35K Sell
87
-46
-35% -$21.3K 0.01% 653
2024
Q3 		$61.5K Buy
133
+109
+454% +$52.4K 0.01% 523
2024
Q2 		$11.3K Hold
24
– – ﹤0.01% 758
2024
Q1 		$9.96K Sell
24
-62
-72% -$26.2K ﹤0.01% 763
2023
Q4 		$35K Hold
86
– – 0.01% 557
2023
Q3 		$29.9K Buy
86
+16
+23% +$5.6K 0.01% 553
2023
Q2 		$24.4K Sell
70
-15
-18% -$5.05K 0.01% 569
2023
Q1 		$26.5K Buy
85
+4
+5% +$1.2K 0.01% 545
2022
Q4 		$23.4K Buy
+81
New +$24.7K 0.01% 545

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Colonial Trust's VRTX Position: Q2 2026 in Review

Colonial Trust held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 21 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Colonial Trust first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. The position peaked at $61.5K in Q3 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Colonial Trust held 21 shares of Vertex Pharmaceuticals worth $10.7K as of Q2 2026.
  • Colonial Trust left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Colonial Trust's portfolio in Q2 2026, its #759 holding.
  • Colonial Trust first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Colonial Trust's Vertex Pharmaceuticals position peaked at $61.5K in Q3 2024.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Colonial Trust's 13F filing for Q2 2026, filed 11 Aug 2026.